Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in chinese adults

Cyp2c19 Genotype ◽

Chinese Adults ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Genotype A

M1119 Sequential Therapy vs. Standard Triple Therapy as Treatment of Helicobacter pylori Infection. A Prospective, Randomized, Parallel-Group, Open-Label Study in Mexico

Gastroenterology ◽

10.1016/s0016-5085(10)61545-4 ◽

2010 ◽

Vol 138 (5) ◽

pp. S-336

Author(s):

Jose M. Remes Troche ◽

Guadalupe Alarcon Rivera ◽

Antonio Ramos-De la Medina ◽

Eli De la Cruz Patiño ◽

Job Reyes Huerta ◽

...

Keyword(s):

Helicobacter Pylori ◽

Triple Therapy ◽

Sequential Therapy ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Standard Triple Therapy ◽

Parallel Group

A Multicenter, Open-Label, Randomized Trial of Vonoprazan Versus PPI Based 7-Day Triple Therapy for the First-Line Treatment of Helicobacter Pylori Infection

Gastroenterology ◽

10.1016/s0016-5085(17)31131-9 ◽

2017 ◽

Vol 152 (5) ◽

pp. S250

Author(s):

Soichiro Sue ◽

Hirohumi Kuwashima ◽

Isao Arima ◽

Marina Ogushi ◽

Satoshi Nakao ◽

...

Keyword(s):

Helicobacter Pylori ◽

Randomized Trial ◽

Triple Therapy ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open-Label Randomized Controlled Trial of Vonoprazan and Esomeprazole in First-Line Triple Therapy Against Helicobacter Pylori Infection

Gastroenterology ◽

10.1016/s0016-5085(17)31120-4 ◽

2017 ◽

Vol 152 (5) ◽

pp. S248

Author(s):

Hiroyuki Tamaki ◽

Masahiro Morita ◽

Teruyo Noda ◽

Masako Izuta ◽

Atsushi Kubo ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Helicobacter Pylori ◽

Triple Therapy ◽

Controlled Trial ◽

First Line ◽

Open Label ◽

Randomized Controlled

An open-label, randomized controlled trial of vonoprazan versus esomeprazole as part of first-line triple therapy for Helicobacter pylori infection

10.26226/morressier.59a6b345d462b80290b547bd ◽

2017 ◽

Author(s):

Hiroyuki Tamaki

Keyword(s):

Randomized Controlled Trial ◽

Helicobacter Pylori ◽

Triple Therapy ◽

Controlled Trial ◽

First Line ◽

Open Label ◽

Randomized Controlled

Sequential Therapy for 10 Days Versus Triple Therapy for 14 Days in the First-line Treatment of Helicobacter pylori Infection— A Multicenter, Open-label, Randomized Trial

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2013.09.043 ◽

2014 ◽

Vol 12 (1) ◽

pp. 161-162 ◽

Cited By ~ 2

Author(s):

Jyh-Ming Liou ◽

Chieh-Chang Chen ◽

Chi-Yang Chang ◽

Jeng-Yi Wu ◽

You-Jen Fang ◽

...

Keyword(s):

Helicobacter Pylori ◽

Randomized Trial ◽

Triple Therapy ◽

Sequential Therapy ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Su1190 Berberine-,Allicin-or Clarithromycin-Based Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection: an Open-Label, Randomized Trial

Gastroenterology ◽

10.1016/s0016-5085(14)61437-2 ◽

2014 ◽

Vol 146 (5) ◽

pp. S-398 ◽

Cited By ~ 4

Author(s):

Xiaomei Zhang ◽

Yunsheng Yang ◽

Sun Gang ◽

Chao Yang ◽

Mingliang Lu ◽

...

Keyword(s):

Helicobacter Pylori ◽

Randomized Trial ◽

Triple Therapy ◽

Line Treatment ◽

First Line ◽

Open Label ◽

437 – An Open-Label, Multi-Center, Randomized, Superiority Trial of Vonoprazan Versus Esomeprazole As Part of First-Line Triple Therapy for Helicobacter Pylori Infection

Gastroenterology ◽

10.1016/s0016-5085(19)37010-6 ◽

2019 ◽

Vol 156 (6) ◽

pp. S-89

Author(s):

Hiroyuki Tamaki ◽

Teruyo Noda ◽

Masahiro Morita ◽

Akina Omura ◽

Atsushi Kubo ◽

...

Keyword(s):

Helicobacter Pylori ◽

Triple Therapy ◽

First Line ◽

Open Label ◽

Superiority Trial

Efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker as first-line treatment for Helicobacter pylori infection

10.26226/morressier.57c53841d462b80296c9c9d4 ◽

2016 ◽

Author(s):

Sho Suzuki

Keyword(s):

Helicobacter Pylori ◽

Triple Therapy ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964930.793468200 ◽

2012 ◽

Author(s):

Yoshio Yamaoka ◽

Seiji Shiota

Keyword(s):

Helicobacter Pylori ◽

Triple Therapy ◽

Randomised Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

Journal of Hepatology ◽

10.1016/j.jhep.2011.07.033 ◽

2012 ◽

Vol 56 (2) ◽

pp. 486-487 ◽

Cited By ~ 6

Author(s):

Jairo A. Garcia ◽

Lewis R. Roberts

Keyword(s):

Hepatocellular Carcinoma ◽

Phase Ii ◽

Advanced Hepatocellular Carcinoma ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy